Logo

Novartis to Acquire AveXis with its Gene Therapy Clinical Candidates

Share this

M&A

Novartis to Acquire AveXis with its Gene Therapy Clinical Candidates

Shots:

  • Novartis acquires AveXis- in all stock transaction with its AVXS-101 candidate for replacing the defective SMN1 gene. AveXis to receive $218/share making total deal value $8.7B
  • The focus of the agreement is to utilize AveXis’ AAV9 gene therapy platform to develop therapies for multiple therapeutic areas
  • AVXS-101 is a gene replacement therapy candidate targeted for spinal muscular atrophy (SMA) Type 1 and has received FDA’s ODD and Breakthrough Therapy Designation for SMA & SMA Type 1

Ref: Novartis | Image:  Twitter


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions